Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

Table 2 Efficacy

Outcome^a	nab-P + Gem N = 83
ORR, n (%)	29 (35)
CR	0
PR	29 (35)
SD, n (%)	18 (22)
PD, n (%)	13 (16)
Not evaluable, n (%)	15 (18)
No postbaseline assessment, n (%)	8 (10)
DCR, n (%)^b	46 (55)
DOR, median (95% CI), months	8.9 (6.01–8.94)
OS, median (95% CI), months	9.2 (7.6–11.1)
OS rate, %
3 months	89
6 months	70
9 months	53
12 months	30
15 months	15
Progression-free survival, median (95% CI), months	5.5 (5.29–7.16)

CR complete response, DCR disease control rate, DOR duration of response, Gem gemcitabine, nab-P nab-paclitaxel, ORR overall response rate, OS overall survival, PD progressive disease, PR partial response, SD stable disease
^aPercents may not add up to 100 due to rounding
^bDefined as the percentage of patients achieving objective tumor response or SD for ≥16 weeks

ISSN: 1471-2407